PSI-353661

• Description:

  PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against HCV infection. PSI-353661 shows EC90s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes[1][3].

• Product Name Alternative:

  GS-558093

• UNSPSC:

  12352005

• Target:

  HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/psi-353661.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=NC(N)=NC2=C1N=CN2[C@@H]([C@@](F)(C)[C@@H]3O)O[C@@H]3CO[P@@](N[C@@H](C)C(OC(C)C)=O)(OC4=CC=CC=C4)=O

• Molecular Formula:

  C24H32FN6O8P

• Molecular Weight:

  582.52

• References & Citations:

  [1]Wonsuk Chang, et al. Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection. ACS Med Chem Lett. 2010 Dec 17;2 (2) :130-5. |[2]Furman PA, et al. Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res. 2011 Aug;91 (2) :120-32. |[3]Yugo Kai, et al. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1231747-08-2]